In:
The Journal of Internal Korean Medicine, The Society of Internal Korean Medicine, Vol. 42, No. 5 ( 2021-10-30), p. 820-832
Abstract:
Objectives: This study examined the case of a patient with ROS1-positive recurrent non-small-cell lung cancer treated with crizotinib and traditional Korean medicine.Methods: The patient was treated with crizotinib from January 20 2021 to May 22 2021, together with 〈 i 〉 Haedogyangpye-tang 〈 /i 〉 and 〈 i 〉 Haengso-tang 〈 /i 〉 . The tumor size was measured using computed tomography (CT), and adverse events were evaluated according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.Results: After four months of combined treatment, the sizes of the lymph nodes in the porta hepatis, hepatoduodenal, retrocrural, aortocaval, and para-aortic areas had decreased, and no lymph nodes larger than 1 cm in diameter were observed. The side effects of chemotherapy also improved.Conclusions: This case study suggests that traditional Korean medicine may alleviate the side effects of chemotherapy, improve quality of life, and complement chemotherapy itself.
Type of Medium:
Online Resource
ISSN:
1226-9174
DOI:
10.22246/jikm.2021.42.5.820
Language:
English
Publisher:
The Society of Internal Korean Medicine
Publication Date:
2021